{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:22:15Z","timestamp":1790144535269,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1038\/nrneph.2015.152","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T05:47:01Z","timestamp":1443505621000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Nephrology research\u2014the past, present and future"],"prefix":"10.1038","volume":"11","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Molitoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"BFnrneph2015152_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck. L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nm.2261","volume":"17","author":"LC Clement","year":"2011","unstructured":"Clement, L. C. et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17, 117\u2013122 (2011).","journal-title":"Nat. Med."},{"key":"BFnrneph2015152_CR3","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1681\/ASN.2014050465","volume":"26","author":"MC Hu","year":"2015","unstructured":"Hu, M. C. et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J. Am. Soc. Nephrol. 26, 1290\u20131302 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nm.1960","volume":"15","author":"A Machnik","year":"2009","unstructured":"Machnik, A. et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat. Med. 15, 545\u2013552 (2009).","journal-title":"Nat. Med."},{"key":"BFnrneph2015152_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/ng.3302","volume":"47","author":"PG Maass","year":"2015","unstructured":"Maass, P. G. et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat. Genet. 47, 647\u2013653 (2015).","journal-title":"Nat. Genet."},{"key":"BFnrneph2015152_CR6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1681\/ASN.2014121192","volume":"9","author":"C Antignac","year":"2015","unstructured":"Antignac, C. et al. The future of polycystic kidney disease research\u2014as seen by the 12 Kaplan awardees. J. Am. Soc. Nephrol. 9, 2081\u20132095 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ki.2014.255","volume":"87","author":"BI Freedman","year":"2015","unstructured":"Freedman, B. I. et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int. 87, 176\u2013181 (2015).","journal-title":"Kidney Int."},{"key":"BFnrneph2015152_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2014050502","volume":"26","author":"M Fresquet","year":"2015","unstructured":"Fresquet, M. et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J. Am. Soc. Nephrol. 26, 302\u2013313 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR9","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nri3523","volume":"13","author":"C Kurts","year":"2013","unstructured":"Kurts, C., Panzer, U., Anders, H. J. & Rees, A. J. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738\u2013753 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrneph2015152_CR10","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1681\/ASN.2014060561","volume":"26","author":"T Hato","year":"2015","unstructured":"Hato, T. et al. The macrophage mediates the renoprotective effects of endotoxin preconditioning. J. Am. Soc. Nephrol. 26, 1347\u20131362 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR11","first-page":"334","volume":"29","author":"AM Hall","year":"2014","unstructured":"Hall, A. M. & Molitoris, B. A. Dynamic multiphoton microscopy: focusing light on acute kidney injury. Physiology (Bethesda) 29, 334\u2013342 (2014).","journal-title":"Physiology (Bethesda)"},{"key":"BFnrneph2015152_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0092-8674(01)00241-0","volume":"104","author":"RP Lifton","year":"2001","unstructured":"Lifton, R. P., Gharavi, A. G. & Geller, D. S. Molecular mechanisms of human hypertension. Cell 104, 545\u2013556 (2001).","journal-title":"Cell"},{"key":"BFnrneph2015152_CR13","doi-asserted-by":"publisher","first-page":"15556","DOI":"10.1073\/pnas.1418342111","volume":"111","author":"S Shibata","year":"2014","unstructured":"Shibata, S. et al. Angiotensin II signaling via protein kinase C phosphorylates Kelch-like 3, preventing WNK4 degradation. Proc. Natl Acad. Sci. USA 111, 15556\u201315561 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2015152_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1097-2765(00)80057-X","volume":"1","author":"M Kestil\u00e4","year":"1998","unstructured":"Kestil\u00e4, M. et al. Positionally cloned gene for a novel glomerular protein\u2014nephrin\u2014is mutated in congenital nephrotic syndrome. Mol. Cell 1, 575\u2013582 (1998).","journal-title":"Mol. Cell"},{"key":"BFnrneph2015152_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/74166","volume":"24","author":"N Boute","year":"2000","unstructured":"Boute, N. et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat. Genet. 24, 349\u2013354 (2000).","journal-title":"Nat. Genet."},{"key":"BFnrneph2015152_CR16","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/S0140-6736(14)60659-0","volume":"383","author":"O Devuyst","year":"2014","unstructured":"Devuyst, O. et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 383, 1844\u20131859 (2014).","journal-title":"Lancet"},{"key":"BFnrneph2015152_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1681\/ASN.2014050489","volume":"26","author":"CE Sadowski","year":"2015","unstructured":"Sadowski, C. E. et al. A single-gene cause in 29.5% of cases of steroid resistant nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1279\u20131289 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2215\/CJN.03770410","volume":"6","author":"S Sant\u00edn","year":"2011","unstructured":"Sant\u00edn, S. et al. Clinical value of NPHS2 analysis in early- and adult-onset steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 6, 344\u2013354 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 329, 841\u2013845 (2010).","journal-title":"Science."},{"key":"BFnrneph2015152_CR20","doi-asserted-by":"crossref","unstructured":"Evolve Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482\u20132494 (2012).","DOI":"10.1056\/NEJMoa1205624"},{"key":"BFnrneph2015152_CR21","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204\u20132213 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR22","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","volume":"361","author":"E Wuhl","year":"2009","unstructured":"Wuhl, E. et al. Strict blood pressure control and progression of renal failure in children. N. Engl. J. Med. 361, 1639\u20131650 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR24","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier, R. W. et al. Blood pressure in early autosomal dominant kidney disease. N. Engl. J. Med. 371, 2255\u20132266 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1056\/NEJMoa0910975","volume":"363","author":"LJ Appel","year":"2010","unstructured":"Appel, L. J. et al. Intensive blood pressure control in hypertensive chronic kidney disease. N. Engl. J. Med. 363, 918\u2013929 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR26","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","volume":"369","author":"A Parsa","year":"2013","unstructured":"Parsa, A. et al. APOL1 risk variants, race and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183\u20132196 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/ki.2011.314","volume":"81","author":"JC He","year":"2012","unstructured":"He, J. C., Chuang, P. Y., Ma'ayan, A. & Iyengar, R. Systems biology of kidney diseases. Kidney Int. 81, 22\u201339 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2015152_CR28","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1681\/ASN.2013111149","volume":"25","author":"A Loupy","year":"2014","unstructured":"Loupy, A. et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J. Am. Soc. Nephrol. 25, 2267\u20132277 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1681\/ASN.2013121322","volume":"25","author":"DG Warnock","year":"2014","unstructured":"Warnock, D. G. & Mauer, M. Fabry disease: dose matters. J. Am. Soc. Nephrol. 25, 653\u2013655 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh, D., Goodship, T. H. & Richards, A. Atypical hemolytic uremic syndrome. Semin. Nephrol. 33, 508\u2013530 (2013).","journal-title":"Semin. Nephrol."},{"key":"BFnrneph2015152_CR31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcp.12136","volume":"76","author":"MY Chang","year":"2013","unstructured":"Chang, M. Y. & Ong, A. C. New treatments for autosomal dominant polycystic kidney disease. Br. J. Clin. Pharmacol. 76, 524\u2013535 (2013).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph2015152_CR32","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa012895","volume":"346","author":"H Debiec","year":"2002","unstructured":"Debiec, H. et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N. Engl. J. Med. 346, 2053\u20132060 (2002).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR33","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","volume":"371","author":"NM Tomas","year":"2014","unstructured":"Tomas, N. M. et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N. Engl. J. Med. 371, 2277\u20132287 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco, P. & Debiec, H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 385, 1983\u20131992 (2015).","journal-title":"Lancet"},{"key":"BFnrneph2015152_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J N\u00fcrnberger","year":"2009","unstructured":"N\u00fcrnberger, J. et al. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 542\u2013544 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo, R. A. & Rother, R. P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N. Engl. J. Med. 360, 544\u2013546 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR37","doi-asserted-by":"publisher","unstructured":"Loirat, C. et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. http:\/\/dx.doi.org\/10.1007\/s00467-015-3076-8 .","DOI":"10.1007\/s00467-015-3076-8"},{"key":"BFnrneph2015152_CR38","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR39","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh, J. et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311, 2518\u20132531 (2014).","journal-title":"JAMA"},{"key":"BFnrneph2015152_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.trsl.2014.11.003","volume":"4","author":"WB LaRivere","year":"2015","unstructured":"LaRivere, W. B., Irazabal, M. V. & Torres, V. E. Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Translat. Res. 4, 488\u2013498 (2015).","journal-title":"Translat. Res."},{"key":"BFnrneph2015152_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1681\/ASN.2013090950","volume":"25","author":"LE Dickson","year":"2014","unstructured":"Dickson, L. E., Wagner, M. C., Sandoval, R. M. & Molitoris, B. A. The proximal tubule and albuminuria: really! J. Am. Soc. Nephrol. 25, 443\u2013453 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR42","doi-asserted-by":"publisher","unstructured":"Wagner, M. C. et al. Proximal tubules have the capacity to regulate uptake of albumin. J. Am. Soc. Nephrol. http:\/\/dx.doi.org\/10.1681\/ASN.2014111107 .","DOI":"10.1681\/ASN.2014111107"},{"key":"BFnrneph2015152_CR43","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2215\/CJN.11141113","volume":"9","author":"JR Prowle","year":"2014","unstructured":"Prowle, J. R. et al. Serum creatinine changes associated with critical illness and detection of persistent renal dysfunction after AKI. Clin. J. Am. Soc. Nephrol. 9, 1015\u20131023 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ki.2013.47","volume":"84","author":"F Gaspari","year":"2013","unstructured":"Gaspari, F. et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 84, 164\u2013173 (2013).","journal-title":"Kidney Int."},{"key":"BFnrneph2015152_CR45","doi-asserted-by":"crossref","unstructured":"GBD Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117\u2013171 (2015).","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"BFnrneph2015152_CR46","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1681\/ASN.2007090970","volume":"19","author":"P Ruggenenti","year":"2008","unstructured":"Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213\u20131224 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrneph.2014.251","volume":"11","author":"VA Luyckx","year":"2015","unstructured":"Luyckx, V. A. & Brenner, B. M. Birth weight, malnutrition and kidney-associated outcomes\u2014a global concern. Nat. Rev. Nephrol. 11, 135\u2013149 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2015152_CR48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ndt\/gfv107","volume":"30","author":"AS De Vriese","year":"2015","unstructured":"De Vriese, A. S. & Fervenza, F. C. Con: biomarkers in glomerular diseases: putting the cart before the wheel? Nephrol. Dial. Transplant. 30, 885\u2013890 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015152_CR49","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfv106","volume":"30","author":"P Ronco","year":"2015","unstructured":"Ronco, P. Moderator's view: biomarkers in glomerular diseases-translated into patient care or lost in translation? Nephrol. Dial. Transplant. 30, 899\u2013902 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015152_CR50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/ki.2013.374","volume":"85","author":"PT Murray","year":"2014","unstructured":"Murray, P. T. et al. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 85, 513\u2013521 (2014).","journal-title":"Kidney Int."},{"key":"BFnrneph2015152_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00281-014-0437-5","volume":"36","author":"P Ronco","year":"2014","unstructured":"Ronco, P. & Floege, J. Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation? Semin. Immunopathol. 36, 377\u2013379 (2014).","journal-title":"Semin. Immunopathol."},{"key":"BFnrneph2015152_CR52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238\u2013248 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR53","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395\u20131407 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR54","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham, J. J. et al. Volume progression in polycystic kidney disease. N. Engl. J. Med. 354, 2122\u20132130 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR55","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","volume":"65","author":"BA Warady","year":"2015","unstructured":"Warady, B. A. et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) cohort. Am. J. Kidney Dis. 65, 878\u2013888 (2015).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2015152_CR56","doi-asserted-by":"publisher","first-page":"a015560","DOI":"10.1101\/cshperspect.a015560","volume":"3","author":"K English","year":"2013","unstructured":"English, K. & Wood, K. J. Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb. Perspect. Med. 3, a015560 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"BFnrneph2015152_CR57","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/ndt\/gfv108","volume":"30","author":"LH Mariani","year":"2015","unstructured":"Mariani, L. H. & Kretzler, M. Pro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism-individual patient variability in disease presentation, course and response to therapy. Nephrol. Dial. Transplant. 30, 892\u2013898 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2015152_CR58","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrneph.2015.6","volume":"11","author":"IG Okpechi","year":"2015","unstructured":"Okpechi, I. G., Swanepoel, C. R. & Venter, F. Access to medications and conducting clinical trials in LMICs. Nat. Rev. Nephrol. 11, 189\u2013194 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph2015152_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/sdi.12346","volume":"28","author":"P Armignacco","year":"2015","unstructured":"Armignacco, P. et al. Wearable devices for blood purification: principles, miniaturization, and technical challenges. Semin. Dial. 28, 125\u2013130 (2015).","journal-title":"Semin. Dial."},{"key":"BFnrneph2015152_CR60","doi-asserted-by":"publisher","first-page":"125096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR\u2013Cas9. Science 346, 125096 (2014).","journal-title":"Science"},{"key":"BFnrneph2015152_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins, F. S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793\u2013795 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR62","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1681\/ASN.2014020150","volume":"25","author":"BA Molitoris","year":"2014","unstructured":"Molitoris, B. A. ASN Presidential Address 2013: innovation and individualization\u2014the path forward for nephrology. J. Am. Soc. Nephrol. 25, 893\u2013897 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2015152_CR63","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/S0140-6736(15)60269-0","volume":"385","author":"R Horton","year":"2015","unstructured":"Horton, R. & Berman, P. Eliminating acute kidney injury by 2015: an achievable goal. Lancet 385, 2551\u20132552 (2015).","journal-title":"Lancet"},{"key":"BFnrneph2015152_CR64","doi-asserted-by":"publisher","first-page":"1257601","DOI":"10.1126\/science.1257601","volume":"347","author":"J Menche","year":"2015","unstructured":"Menche, J. et al. Disease networks. Uncovering disease\u2013disease relationships through the incomplete interactome. Science. 347, 1257601 (2015).","journal-title":"Science."},{"key":"BFnrneph2015152_CR65","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1056\/NEJMc1213779","volume":"368","author":"T Kawai","year":"2013","unstructured":"Kawai, T., Sachs, D. H., Sykes, M. & Cosimi, A. B. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 368, 1850\u20131852 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2015152_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/01.mnh.0000437332.31418.e0","volume":"23","author":"BD Humphreys","year":"2014","unstructured":"Humphreys, B. D. Kidney injury, stem cells and regeneration. Curr. Opin. Nephrol. Hypertens. 23, 25\u201331 (2014).","journal-title":"Curr. Opin. Nephrol. Hypertens."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2015.152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T12:39:53Z","timestamp":1718109593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2015.152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["BFnrneph2015152"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2015.152","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]},"assertion":[{"value":"29 September 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F. has consulted for and\/or received speaker honoraria from Amgen, Abbvie, Chugai, Fresenius, Pharmalink, Sanofi and Vifor. B.A.M. is co-founder and Medical Director of FAST BioMedical, a company developing technology to rapidly quantify plasma volume and glomerular filtration rate. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}